erlotinib tablet
1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 ) Limitations of Use: Safety and efficacy of erlotinib have not been established in patients with NSCLC whose tumors have other EGFR mutations. ( 1.1 ) Erlotinib is not recommended for use in combination with platinum-based chemotherapy. ( 1.1 ) 1.1 Non-Small Cell Lung Cancer (NSCLC) Erlotinib tablets are indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen [see Clinical Studies ( 14.1 , 14.3 )]. Limitations of use: Safety and efficacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations [see Clinical Studies ( 14.1 , 14.2 )] . Erlotinib tablets are not recommended for use in combination with platinum-based chemotherapy [see Clinical Studies ( 14.4 )] . 1.2 Pancreatic Cancer Erlotinib tablets in combination with gemcitabine are indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer [see Clinical Studies ( 14.5 )] .
zydus pharmaceuticals (usa) inc.
ROUND WHITE 913
Related Pills
erlotinib tablet
zydus pharmaceuticals (usa) inc.
erlotinib tablet
zydus pharmaceuticals (usa) inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING
ERLOTINIB Tablets equivalent to 25 mg of
ERLOTINIB are white to off-white, round, film-coated tablets, debossed with '913' on one side and plain on other side and are supplied as follows: NDC 68382-913-06 in bottles of 30 tablets with child-resistant closure NDC 68382-913-16 in bottles of 90 tablets with child-resistant closure NDC 68382-913-84 in unit-dose blister cartons of 30 tablets (3 x 10 unit-dose)
ERLOTINIB Tablets equivalent to 100 mg of
ERLOTINIB are white to off-white, round, film-coated tablets, debossed with '914' on one side and plain on other side and are supplied as follows: NDC 68382-914-06 in bottles of 30 tablets with child-resistant closure NDC 68382-914-16 in bottles of 90 tablets with child-resistant closure NDC 68382-914-84 in unit-dose blister cartons of 30 tablets (3 x 10 unit-dose)
ERLOTINIB Tablets equivalent to 150 mg of
ERLOTINIB are white to off-white, round, film-coated tablets, debossed with '915' on one side and plain on other side and are supplied as follows: NDC 68382-915-06 in bottles of 30 tablets with child-resistant closure NDC 68382-915-16 in bottles of 90 tablets with child-resistant closure NDC 68382-915-84 in unit-dose blister cartons of 30 tablets (3 x 10 unit-dose) Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
More pills like ROUND 913